Modern a Biotech - Search News

Moderna, COVID

Moderna fronts $950M to settle yearslong COVID patent litigation with Genevant, Arbutus

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. | Moderna will pay $950 million upfront—and no future royalties—to settle patent litigation over its mRNA-based vaccine Spikevax.

· 12h

Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang

· 1d

Moderna’s stock rallies as settlement of a patent dispute clears vaccine pipeline

· 9h

Moderna Stock Shoots Up on $2.3 Billion Patent Settlement

Moderna shares surged 16% Wednesday to their highest level since 2024 after the company agreed to pay up to $2.25 billion to two other biotechnology companies to settle patent litigation over its Covi...

· 4h

Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock.

STAT · 1d

Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind mRNA vaccines

The Pharma Letter

Genevant and Arbutus agree $2.25 billion global settlement with Moderna

Roivant announced that its subsidiary Genevant Sciences and Arbutus Biopharma have entered into a $2.25 billion global settlement with Moderna to resolve all US and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines,

Fierce Biotech

FDA accepts filing for Moderna flu vaccine after swift rethink

The FDA has accepted Moderna’s revised influenza vaccine filing days after controversially refusing to review the original submission, putting the biotech on track to win approval in time for the 2026-27 flu season.

Hosted on MSN

Moderna’s rally ripples through biotech and health care ETFs

Shares of Moderna (MRNA) have surged sharply this week, drawing renewed attention to exchange traded funds with significant exposure to the U.S. pharmaceutical and biotechnology company. The stock climbed 9.7% on Thursday alone and is up 28.9% over the ...

STAT

Inside Moderna’s rapid rise — and precarious future

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a Hollywood screenplay. In its relatively short life, it ...

16d

Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders

MRNA shares jumped 5.3% as investors rotated into large-cap biotech, betting on its expanding pipeline in volatile trade.

AOL

Moderna: Stock to Avoid or Bad News Buy?

A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The stock soared more than 700% through 2020 and into the first ...

STAT

Moderna’s president weighs in on FDA’s decision not to review its flu vaccine

Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the ...

The Motley Fool

Telemark Asset Management Builds Position in Beaten-Down Biotech Stock.

Moderna, Inc. is a biotechnology company specializing in the discovery and development of mRNA-based medicines. The company leverages its mRNA technology platform to address a broad range of diseases, with a pipeline spanning infectious disease vaccines ...